Leica Biosystems Unveils its Compact Capacity, Feature-Rich Digital Pathology Scanner at Asia Pacific Summit
VISTA, California – August 5, 2025 — Reinforcing its leadership in digital pathology for cancer diagnostics and research, Leica Biosystems proudly unveiled its Aperio GT 180 scanner at the Asia Pacific Imaging Summit 2025 — 9th Digital Pathology & AI Congress.
Building on more than 25 years of innovation, the Aperio GT 180 scanner represents the next step in Leica Biosystems slide scanning portfolio. While offering a more compact 180-slide capacity compared to its predecessor, the Aperio GT 450, the GT 180 retains the trusted speed and reliability that defines the Aperio platform. It hosts a suite of scalable, workflow-enhancing features designed to streamline operations and accelerate scientific discovery.
“Researchers are embracing the Aperio GT 180 for its precision and adaptability,” said Bryce Brown, Director, Product Management - Digital Pathology. “With native DICOM-compatible output at both 20x and 40x magnification, Z-Stacking, Extended Focus, and Default Calibration, the Aperio GT 180 delivers the flexibility needed across diverse pathology workflows. And with its enhanced Manual Scan mode complementing our automated load-and-go functionality, users can confidently capture even the most challenging slides with clarity and consistency.”
With user feedback driving product refinement, the company’s leadership is doubling down on its mission to transform pathology workflows.
“At Leica Biosystems, we’re not just expanding our portfolio — we're redefining Digital Pathology,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “Our relentless focus on innovation empowers all of our customers, large or small, to stay ahead of the curve and push the boundaries of translational research.”
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.
For Research Use Only. Not For Use in Diagnostic Procedures.
